The pharmacotherapeutic management of episodic and chronic migraine with gepants
Sign Up to like & getrecommendations! Published in 2023 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2023.2201375
Abstract: ABSTRACT Introduction The small molecule non-peptide calcitonin gene-related peptide (CGRP) receptor antagonists named gepants offer a breakthrough novel approach in migraine acute and prophylactic drug treatment. This review aimed to determine the place of gepants… read more here.
Keywords: migraine; chronic migraine; pharmacotherapeutic management; treatment ... See more keywords
Fremanezumab as a preventive treatment for episodic and chronic migraine
Sign Up to like & getrecommendations! Published in 2019 at "Expert Review of Neurotherapeutics"
DOI: 10.1080/14737175.2019.1614742
Abstract: ABSTRACT Introduction: The importance of calcitonin gene-related peptide (CGRP) in migraine pathogenesis is well established. Fremanezumab is a humanized IgG2a monoclonal antibody that binds to CGRP. Areas covered: In this paper, we review the development… read more here.
Keywords: migraine; treatment episodic; episodic chronic; fremanezumab preventive ... See more keywords
Polyamines serum levels in episodic and chronic migraine
Sign Up to like & getrecommendations! Published in 2020 at "Expert Review of Neurotherapeutics"
DOI: 10.1080/14737175.2021.1862650
Abstract: ABSTRACT Background: Previous studies focused on food as the trigger of a migraine attack did not consider polyamines as possible activators and sensitizers of the trigeminal-vascular system through their interaction with NMDA glutamate receptors. Therefore,… read more here.
Keywords: migraine; polyamines serum; episodic chronic; serum levels ... See more keywords
Review of Tolerability of Fremanezumab for Episodic and Chronic Migraine
Sign Up to like & getrecommendations! Published in 2023 at "Neuropsychiatric Disease and Treatment"
DOI: 10.2147/ndt.s371686
Abstract: Abstract Calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) were the first class of medication specifically developed for the prevention of migraine. Fremanezumab is one of four CGRP mAbs currently available and is approved by the… read more here.
Keywords: review; tolerability; migraine; chronic migraine ... See more keywords